Clinical Topics & News

Serum Interferon-γ Is a Psoriasis Severity and Prognostic Marker

Author and Disclosure Information

The aim of this study was to measure serum interferon-γ (IFN-γ) levels in participants with different types and severities of psoriasis. The study was conducted on 21 participants with psoriasis. Participants were divided into 3 groups according to disease severity: erythrodermic, severe plaque, and mild to moderate plaque psoriasis. Fifteen participants received different treatment modalities for 16 weeks and were followed for an additional 12 weeks. The enzyme-linked immunosorbent assay technique was used to measure serum IFN-g levels in participants before treatment and compared with matched controls and participants receiving treatment. Significant differences were detected between participants and controls in mean serum IFN-g levels before treatment (P<.05 there was a positive correlation between serum ifn-g levels and psoriasis area severity index scores clinical type of with the highest in erythrodermic group lowest mild to moderate plaque group. irrespective treatment participants who showed improvement disease condition significant decrease pasi also had class="article_abstract_nonital">P<.05 moreover participants with serum ifn-g levels that did not dramatically decrease had a shorter remission period compared those who showed significant in levels. the substantial elevation and variation according to disease severity suggest has role determining therapy evaluation which encourages further research on anti biologic treatment of psoriasis.>


 

Recommended Reading

Dead Sea Minerals
MDedge Dermatology
Data Watch: Incidence of Cutaneous Lupus Erythematosus, 1965&#150;2005
MDedge Dermatology
Cutaneous Lupus Found Refractory in Almost 8%
MDedge Dermatology
SLE Guidelines for Clinical Practice Announced
MDedge Dermatology
PsA, Others Join Diabetes as CVD Risk Factors
MDedge Dermatology
Belimumab Shows Effectiveness in Phase III Trial
MDedge Dermatology
Add Vascular Disease to List of Psoriasis Risks
MDedge Dermatology
New Scleroderma-Modifying Therapies Emerging
MDedge Dermatology
Skin Changes Help Identify Scleroderma Mimics
MDedge Dermatology
Skin Elasticity May Serve as Potential Biomarker for Sclerosis
MDedge Dermatology